ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,222.68
0.16%
US Tech 100
17,650.00
0.05%
다우존스 지수
39,512.84
0.32%
Bitcoin
61,139.68
0.57%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. MannKind Corporation (MNKD)

  7. MannKind Corporation (MNKD) 뉴스

MNKD

MannKind (MNKD)

MannKind Corporation
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:MNKD
일자시간출처헤드라인심볼기업
2024/05/0905:18GlobeNewswire Inc.MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
2024/05/0905:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNKDMannKind Corporation
2024/05/0905:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
2024/05/0619:05GlobeNewswire Inc.MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
2024/05/0205:00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
2024/04/3019:05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
2024/04/2919:05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
2024/04/0319:00GlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
2024/03/2705:05GlobeNewswire Inc.MannKind Announces CFO TransitionNASDAQ:MNKDMannKind Corporation
2024/03/1119:05GlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsNASDAQ:MNKDMannKind Corporation
2024/03/0520:05GlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8NASDAQ:MNKDMannKind Corporation
2024/03/0503:01GlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
2024/02/2806:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
2024/02/2806:00GlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
2024/02/2020:00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024NASDAQ:MNKDMannKind Corporation
2024/02/1520:05GlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®NASDAQ:MNKDMannKind Corporation
2024/02/0520:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
2024/02/0520:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
2024/02/0520:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
2024/02/0520:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
2024/02/0520:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
2024/02/0520:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
2024/01/0220:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
2024/01/0220:05GlobeNewswire Inc.MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionNASDAQ:MNKDMannKind Corporation
2023/12/2820:00GlobeNewswire Inc.MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
2023/12/2806:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
2023/12/1611:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
2023/12/1606:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
2023/12/1509:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
2023/12/1506:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
 검색 관련기사 보기:NASDAQ:MNKD

최근 히스토리

NYSE
JPM
JP Morgan Chase
FX
USDEUR
US Dollar vs Euro
NASDAQ
NVDA
NVIDIA
CCOM
US30
US 30
AMEX
XLV
Health Care Select Sector
NYSE
MCD
McDonalds
PM
XAUUSD
Gold vs US Dollar
COIN
SOLUSD
Solana
USI
USTECH100
US Tech 100
AMEX
XLE
Energy Select Sector SPDR
FX
USDJPY
US Dollar vs Yen
USOTC
BNPQY
BNP Paribas (QX)
COIN
ETHUSD
Ethereum
AMEX
XLF
Financial Select Sector
NYSE
XOM
Exxon Mobil
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유